Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anogenital warts treatment options: a practical approach.
Delmonte S, Benardon S, Cariti C, Ribero S, Ramoni S, Cusini M. Delmonte S, et al. Among authors: cariti c. G Ital Dermatol Venereol. 2020 Jun;155(3):261-268. doi: 10.23736/S0392-0488.18.06125-4. Epub 2018 Sep 24. G Ital Dermatol Venereol. 2020. PMID: 30251804 Free article. Review.
Infections in Sézary syndrome: A retrospective cohort study of 113 patients.
Cariti C, Quaglino P, Lupia T, Novelli M, Marra E, Fava P, Caliendo V, Tonella L, De Rosa FG, Fierro MT, Ribero S. Cariti C, et al. J Am Acad Dermatol. 2022 Apr;86(4):943-946. doi: 10.1016/j.jaad.2021.03.079. Epub 2021 May 8. J Am Acad Dermatol. 2022. PMID: 33975758 No abstract available.
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study.
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, Cariti C, Viola R, Stroppiana E, Verrone A, Ortoncelli M, Quaglino P, Ribero S. Dapavo P, et al. Among authors: cariti c. J Dermatolog Treat. 2022 Jun;33(4):2352-2357. doi: 10.1080/09546634.2021.1961998. Epub 2021 Aug 13. J Dermatolog Treat. 2022. PMID: 34315331
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients.
Cariti C, Dapavo P, Mastorino L, Ortoncelli M, Siliquini N, Merli M, Avallone G, Giordano S, Fabrizio R, Susca S, Verrone A, Stroppiana E, Quaglino P, Ribero S. Cariti C, et al. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e233-e235. doi: 10.1111/jdv.17766. Epub 2021 Nov 7. J Eur Acad Dermatol Venereol. 2022. PMID: 34672026 No abstract available.
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients.
Mastorino L, Castelli F, Stroppiana E, Verrone A, Ortoncelli M, Susca S, Boskovic S, Passerini SG, Macagno N, Cariti C, Licciardello M, Solaroli C, Pertusi G, Aragone MG, Baggini G, Addese C, Leporati C, Peila R, Giura MT, Rossotto G, Pella P, Mocci L, Merlo G, Tiberio R, Graziola F, Quaglino P, Dapavo P, Ribero S. Mastorino L, et al. Among authors: cariti c. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e838-e841. doi: 10.1111/jdv.18314. Epub 2022 Jun 22. J Eur Acad Dermatol Venereol. 2022. PMID: 35686942 No abstract available.
21 results